LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read moreThu, 13th Sep 2012 14:56
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:
Read more(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.
Read more(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.
Read more(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.
Read more(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.
Read more(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.
Read more(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.
Read moreGSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.
Read more(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.
Read more(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.
Read more(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.
Read moreThursday 26 October | |
Bank of Ireland Group PLC | Trading Statement |
Bloomsbury Publishing PLC | Half Year Results |
Botswana Diamonds PLC | Trading Statement |
C&C Group PLC | Half Year Results |
e-Therapeutics PLC | Half Year Results |
Financials Acquisition Corp | Trading Statement |
GCP Infrastructure Investments Ltd | Trading Statement |
HarbourVest Global Private Equity Ltd | Half Year Results |
Hummingbird Resources PLC | Trading Statement |
Hunting PLC | Trading Statement |
Inchcape PLC | Trading Statement |
International Personal Finance PLC | Trading Statement |
PPHE Hotel Group Ltd | Trading Statement |
Renishaw PLC | Trading Statement |
Standard Chartered PLC | Q3 Results |
Unilever PLC | Trading Statement |
WPP PLC | Trading Statement |
Friday 27 October | |
International Consolidated Airlines Group SA | Q3 Results |
NatWest Group PLC | Q3 Results |
Monday 30 October | |
Airtel Africa PLC | Half Year Results |
Computacenter PLC | Trading Statement |
Glencore PLC | Trading Statement |
HSBC Holdings PLC | Q3 Results |
Lok'n Store Group PLC | Full Year Results |
Pearson PLC | Trading Statement |
Tuesday 31 October | |
BP PLC | Q3 Results |
Coca-Cola HBC AG | Trading Statement |
Elementis PLC | Trading Statement |
essensys PLC | Full Year Results |
Georgia Capital PLC | Q3 Results |
Grit Real Estate Income Group Ltd | Full Year Results |
RHI Magnesita NV | Trading Statement |
Spectris PLC | Q3 Results |
TP ICAP Group PLC | Trading Statement |
UP Global Sourcing Holdings PLC | Full Year Results |
Wednesday 1 November | |
Asos PLC | Full Year Results |
Aston Martin Lagonda Global Holdings PLC | Q3 Results |
Beximco Pharmaceuticals Ltd | Full Year Results |
GSK PLC | Q3 Results |
Next PLC | Trading Statement |
Smurfit Kappa Group PLC | Trading Statement |
Weir Group PLC | Trading Statement |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.
Read more(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.
Read more